Jan Vesterbacka
Overview
Explore the profile of Jan Vesterbacka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
670
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen P, Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, et al.
EBioMedicine
. 2024 Oct;
109:105385.
PMID: 39395230
Background: Immunocompromised patients with primary and secondary immunodeficiencies have shown impaired responses to SARS-CoV-2 mRNA vaccines, necessitating recommendations for additional booster doses. However, longitudinal data reflecting the real-world impact of...
2.
Narayanan A, Kieri O, Vesterbacka J, Manoharan L, Chen P, Ghorbani M, et al.
Sci Rep
. 2024 Aug;
14(1):17820.
PMID: 39090139
The gut and oral microbiome is altered in people living with HIV (PLWH). While antiretroviral treatment (ART) is pivotal in restoring immune function in PLWH, several studies have identified an...
3.
Vesterbacka J, Svensson A, Nowak P
AIDS Rev
. 2024 Mar;
26(1):41-47.
PMID: 38530748
Sweden is a country with a low prevalence of human lymphotropic T-cell virus (HTLV) infection, estimated at < 0.005%, but the infection rate is notably higher in specific risk groups...
4.
Muller T, Gao Y, Wu J, Ribeiro O, Chen P, Bergman P, et al.
Cell Host Microbe
. 2024 Jan;
32(2):156-161.e3.
PMID: 38211584
T cells are critical in mediating the early control of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection. However, it remains unknown whether memory T cells can effectively cross-recognize...
5.
Sunden-Cullberg J, Chen P, Habel H, Skorup P, Janols H, Rasmuson J, et al.
PLoS One
. 2023 Dec;
18(12):e0295838.
PMID: 38157348
Background: Anakinra and tocilizumab are used for severe Covid-19, but only one previous randomized controlled trial (RCT) has studied both. We performed a multi-center RCT comparing anakinra or tocilizumab versus...
6.
Ray S, Narayanan A, Vesterbacka J, Blennow O, Chen P, Gao Y, et al.
NPJ Biofilms Microbiomes
. 2023 Dec;
9(1):104.
PMID: 38123600
Although mRNA SARS-CoV-2 vaccines are generally safe and effective, in certain immunocompromised individuals they can elicit poor immunogenic responses. Among these individuals, people living with HIV (PLWH) have poor immunogenicity...
7.
Kamal H, Lindahl K, Ingre M, Gahrton C, Karkkonen K, Nowak P, et al.
Liver Int
. 2023 Oct;
44(1):228-240.
PMID: 37904316
Background And Aims: Previous studies have shown suboptimal screening for hepatitis D virus (HDV) among patients with chronic hepatitis B (CHB). This study presents the cascade of care for HDV...
8.
Chen P, Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, et al.
EBioMedicine
. 2023 Jul;
94:104700.
PMID: 37453361
Background: Immunocompromised patients have varying responses to SARS-CoV-2 mRNA vaccination. However, there is limited information available from prospective clinical trial cohorts with respect to long-term immunogenicity-related responses in these patient...
9.
Muller T, Sekine T, Trubach D, Niessl J, Chen P, Bergman P, et al.
Sci Transl Med
. 2023 Jul;
15(704):eadg9452.
PMID: 37437015
Suboptimal immunity to SARS-CoV-2 mRNA vaccination has frequently been observed in individuals with various immunodeficiencies. Given the increased antibody evasion properties of emerging SARS-CoV-2 subvariants, it is necessary to assess...
10.
Blennow O, Vesterbacka J, Tovatt T, Nowak P
Clin Infect Dis
. 2023 Feb;
76(10):1864-1865.
PMID: 36782402
No abstract available.